Sysmex Corporation

DB:0YX Stock Report

Market Cap: €11.1b

Sysmex Valuation

Is 0YX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0YX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0YX (€17.4) is trading above our estimate of fair value (€16.87)

Significantly Below Fair Value: 0YX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0YX?

Key metric: As 0YX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 0YX. This is calculated by dividing 0YX's market cap by their current earnings.
What is 0YX's PE Ratio?
PE Ratio34x
EarningsJP¥53.46b
Market CapJP¥1.82t

Price to Earnings Ratio vs Peers

How does 0YX's PE Ratio compare to its peers?

The above table shows the PE ratio for 0YX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21.5x
AFX Carl Zeiss Meditec
22.4x16.1%€4.0b
SHL Siemens Healthineers
30x14.2%€58.3b
EUZ Eckert & Ziegler
25.9x5.2%€929.3m
DRW3 Drägerwerk KGaA
7.6x2.0%€807.0m
0YX Sysmex
34x13.1%€1.8t

Price-To-Earnings vs Peers: 0YX is expensive based on its Price-To-Earnings Ratio (34x) compared to the peer average (21.5x).

Price to Earnings Ratio vs Industry

How does 0YX's PE Ratio compare vs other companies in the European Medical Equipment Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
0YX 34.0xIndustry Avg. 29.6xNo. of Companies9PE01632486480+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 0YX is expensive based on its Price-To-Earnings Ratio (34x) compared to the European Medical Equipment industry average (29.6x).

Price to Earnings Ratio vs Fair Ratio

What is 0YX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0YX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34x
Fair PE Ratio29.9x

Price-To-Earnings vs Fair Ratio: 0YX is expensive based on its Price-To-Earnings Ratio (34x) compared to the estimated Fair Price-To-Earnings Ratio (29.9x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0YX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€17.40
€20.77
+19.4%
11.1%€24.18€16.31n/a14
Dec ’25€20.40
€21.00
+3.0%
10.4%€24.63€16.61n/a14
Nov ’25€16.30
€18.86
+15.7%
12.0%€22.83€15.80n/a14
Oct ’25€19.00
€19.10
+0.5%
11.7%€22.50€15.62n/a15
Sep ’25€17.10
€18.83
+10.1%
11.2%€22.01€15.28n/a14
Aug ’25€15.00
€18.31
+22.0%
12.4%€21.40€14.64n/a14
Jul ’25€14.20
€18.53
+30.5%
12.8%€21.59€14.77n/a14
Jun ’25€16.80
€18.00
+7.1%
12.7%€21.52€14.72n/a12
May ’25€14.70
€18.61
+26.6%
12.0%€22.30€15.26n/a13
Apr ’25€16.00
€18.67
+16.7%
12.0%€22.38€15.10n/a13
Mar ’25€16.67
€18.69
+12.1%
12.0%€22.38€15.11n/a13
Feb ’25€16.13
€18.86
+16.9%
12.2%€23.03€15.75n/a13
Jan ’25€16.27
€19.21
+18.1%
12.2%€23.57€16.12n/a13
Dec ’24€16.20
€18.60
+14.8%
11.8%€22.88€15.65€20.4014
Nov ’24€14.87
€18.62
+25.2%
11.8%€23.10€15.80€16.3013
Oct ’24€14.67
€19.11
+30.3%
11.8%€23.23€16.52€19.0011
Sep ’24€16.13
€19.31
+19.7%
12.6%€25.42€16.94€17.1010
Aug ’24€19.83
€21.16
+6.7%
10.8%€25.56€17.68€15.0011
Jul ’24€20.33
€21.23
+4.4%
15.0%€27.18€17.55€14.2011
Jun ’24€20.17
€21.60
+7.1%
14.1%€26.86€17.68€16.8012
May ’24€19.00
€20.49
+7.9%
12.6%€25.98€17.54€14.7012
Apr ’24€19.33
€21.68
+12.1%
13.3%€27.52€18.58€16.0012
Mar ’24€18.00
€22.17
+23.2%
13.7%€27.60€18.64€16.6713
Feb ’24€19.67
€22.06
+12.2%
13.9%€27.46€18.54€16.1313
Jan ’24€18.67
€22.17
+18.8%
14.8%€27.89€16.97€16.2713
Dec ’23€19.67
€22.01
+11.9%
14.8%€27.63€16.81€16.2013

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 06:09
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sysmex Corporation is covered by 35 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yoshitsugu SasakiAizawa Securities Co. Ltd.
Masahiro NakanomyoBarclays
Craig NelsonBNP Paribas Securities (Asia)